KMT2D links TGF‐β signaling to noncanonical activin pathway and regulates pancreatic cancer cell plasticity

Although KMT2D, also known as MLL2, is known to play an essential role in development, differentiation, and tumor suppression, its role in pancreatic cancer development is not well understood. Here, we discovered a novel signaling axis mediated by KMT2D, which links TGF‐β to the activin A pathway. We found that TGF‐β upregulates a microRNA, miR‐147b, which in turn leads to post‐transcriptional silencing of KMT2D. Loss of KMT2D induces the expression and secretion of activin A, which activates a noncanonical p38 MAPK‐mediated pathway to modulate cancer cell plasticity, promote a mesenchymal phenotype, and enhance tumor invasion and metastasis in mice. We observed a decreased KMT2D expression in human primary and metastatic pancreatic cancer. Furthermore, inhibition or knockdown of activin A reversed the protumoral role of KMT2D loss. These findings support a tumor‐suppressive role of KMT2D in pancreatic cancer and identify miR‐147b and activin A as novel therapeutic targets.

[1]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[2]  Tae Hyun Kim,et al.  Comprehensive Cancer Panel Sequencing Defines Genetic Diversity and Changes in the Mutational Characteristics of Pancreatic Cancer Patients Receiving Neoadjuvant Treatment , 2019, Gut and liver.

[3]  D. Hyman,et al.  First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors , 2019, Clinical Cancer Research.

[4]  J. Iovanna,et al.  Pancreatic Cancer Heterogeneity Can Be Explained Beyond the Genome , 2019, Front. Oncol..

[5]  C. Bult,et al.  miR-147b-mediated TCA cycle dysfunction and pseudohypoxia initiate drug tolerance to EGFR inhibitors in lung adenocarcinoma , 2019, Nature Metabolism.

[6]  S. Johnsen,et al.  DeltaNp63-dependent super enhancers define molecular identity in pancreatic cancer by an interconnected transcription factor network , 2018, Proceedings of the National Academy of Sciences.

[7]  D. Tuveson,et al.  TP63-Mediated Enhancer Reprogramming Drives the Squamous Subtype of Pancreatic Ductal Adenocarcinoma , 2018, Cell reports.

[8]  K. Struhl,et al.  Lysine methyltransferase 2D regulates pancreatic carcinogenesis through metabolic reprogramming , 2018, Gut.

[9]  N. Sharma,et al.  KMT2D Mutation Is Associated With Poor Prognosis in Non–Small‐Cell Lung Cancer , 2018, Clinical lung cancer.

[10]  E. Snyder,et al.  The role of lineage specifiers in pancreatic ductal adenocarcinoma. , 2018, Journal of gastrointestinal oncology.

[11]  I. Sheyhidin,et al.  High MLL2 expression predicts poor prognosis and promotes tumor progression by inducing EMT in esophageal squamous cell carcinoma , 2018, Journal of Cancer Research and Clinical Oncology.

[12]  Yong Wang,et al.  MicroRNA miR-147b promotes tumor growth via targeting UBE2N in hepatocellular carcinoma , 2017, Oncotarget.

[13]  Brandon Da Silva,et al.  Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis , 2017, Cell.

[14]  T. Olencki,et al.  Differential mutation frequencies in metastatic cutaneous squamous cell carcinomas versus primary tumors , 2017, Cancer.

[15]  A. Feinberg,et al.  Epigenomic reprogramming during pancreatic cancer progression links anabolic glucose metabolism to distant metastasis , 2017, Nature Genetics.

[16]  Johannes G. Reiter,et al.  Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer , 2017, Nature Genetics.

[17]  J. Fitzgibbon,et al.  Reduced Expression of Histone Methyltransferases KMT2C and KMT2D Correlates with Improved Outcome in Pancreatic Ductal Adenocarcinoma. , 2016, Cancer research.

[18]  Jeremy MG Taylor,et al.  Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma , 2016, Head & neck.

[19]  P. Zandstra,et al.  A Multi-Lineage Screen Reveals mTORC1 Inhibition Enhances Human Pluripotent Stem Cell Mesendoderm and Blood Progenitor Production , 2016, Stem cell reports.

[20]  C. Iacobuzio-Donahue,et al.  TGF-β Tumor Suppression through a Lethal EMT , 2016, Cell.

[21]  R. Gibbs,et al.  Genomic analyses identify molecular subtypes of pancreatic cancer , 2016, Nature.

[22]  Qingbing Wang,et al.  KDM4B promotes epithelial-mesenchymal transition through up-regulation of ZEB1 in pancreatic cancer. , 2015, Acta biochimica et biophysica Sinica.

[23]  M. Spehlmann,et al.  Activin and TGFβ use diverging mitogenic signaling in advanced colon cancer , 2015, Molecular Cancer.

[24]  Jen Jen Yeh,et al.  Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma , 2015, Nature Genetics.

[25]  K. Basso,et al.  Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis , 2015, Nature Medicine.

[26]  Mohsin Bashir,et al.  Activin-A signaling promotes epithelial–mesenchymal transition, invasion, and metastatic growth of breast cancer , 2015, npj Breast Cancer.

[27]  M. Ljungman,et al.  Transcriptional and post-transcriptional regulation of nucleotide excision repair genes in human cells. , 2015, Mutation research.

[28]  Yali Dou,et al.  Hijacked in cancer: the KMT2 (MLL) family of methyltransferases , 2015, Nature Reviews Cancer.

[29]  A. Dingwall,et al.  The cancer COMPASS: navigating the functions of MLL complexes in cancer. , 2015, Cancer genetics.

[30]  J. Kench,et al.  Whole genomes redefine the mutational landscape of pancreatic cancer , 2015, Nature.

[31]  S. Bekiranov,et al.  Activin upregulation by NF-κB is required to maintain mesenchymal features of cancer stem-like cells in non-small cell lung cancer. , 2015, Cancer research.

[32]  L. Baldini,et al.  MicroRNA as potential biomarker in HCV-associated diffuse large B-cell lymphoma , 2014, Journal of Clinical Pathology.

[33]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[34]  T. E. Wilson,et al.  Use of Bru-Seq and BruChase-Seq for genome-wide assessment of the synthesis and stability of RNA. , 2014, Methods.

[35]  E. Gerner,et al.  Extracellular DNA in pancreatic cancer promotes cell invasion and metastasis. , 2013, Cancer research.

[36]  Nina M. Muñoz,et al.  Targeting TGF-β signaling in cancer , 2013, Expert opinion on therapeutic targets.

[37]  Cun-Yu Wang,et al.  Histone Demethylase KDM6B Promotes Epithelial-Mesenchymal Transition* , 2012, The Journal of Biological Chemistry.

[38]  J. Massagué.  TGFβ signalling in context , 2012, Nature Reviews Molecular Cell Biology.

[39]  Sabine Werner,et al.  The bright and the dark sides of activin in wound healing and cancer , 2012, Journal of Cell Science.

[40]  C. Heldin,et al.  Regulation of EMT by TGFβ in cancer , 2012, FEBS letters.

[41]  C. Heeschen,et al.  Pancreatic stellate cells form a niche for cancer stem cells and promote their self-renewal and invasiveness , 2012, Cell cycle.

[42]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[43]  Manuel Hidalgo,et al.  Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. , 2011, Cell stem cell.

[44]  V. Keshamouni,et al.  Glycogene Expression Alterations Associated with Pancreatic Cancer Epithelial-Mesenchymal Transition in Complementary Model Systems , 2010, PloS one.

[45]  C. Heldin,et al.  Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. , 2009, Current opinion in cell biology.

[46]  Andrei V Bakin,et al.  TAK1 is required for TGF-β1-mediated regulation of matrix metalloproteinase-9 and metastasis , 2007, Oncogene.

[47]  C. Croce,et al.  MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. , 2007, JAMA.

[48]  Stefano Volinia,et al.  MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[50]  B. Vanderhyden,et al.  Inhibin resistance is associated with aggressive tumorigenicity of ovarian cancer cells. , 2005, Molecular cancer research : MCR.

[51]  Wei Gu,et al.  Acetylation inactivates the transcriptional repressor BCL6 , 2002, Nature Genetics.

[52]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[53]  Y. Hayashi,et al.  The role of activin type I receptors in activin A-induced growth arrest and apoptosis in mouse B-cell hybridoma cells. , 1998, Cellular signalling.

[54]  J. Gurdon,et al.  Activin has direct long-range signalling activity and can form a concentration gradient by diffusion , 1997, Current Biology.

[55]  P. Lemaire,et al.  Activin signalling and response to a morphogen gradient , 1994, Nature.

[56]  M. Mercola,et al.  Morphological differences in Xenopus embryonic mesodermal cells are specified as an early response to distinct threshold concentrations of activin. , 1994, Development.

[57]  H. Friess,et al.  Enhanced expression of transforming growth factor β isoforms in pancreatic cancer correlates with decreased survival , 1993 .

[58]  J. Smith,et al.  Responses of embryonic xenopus cells to activin and FGF are separated by multiple dose thresholds and correspond to distinct axes of the mesoderm , 1992, Cell.

[59]  K. Van Nimmen,et al.  Identification of a potent Xenopus mesoderm-inducing factor as a homologue of activin A , 1990, Nature.

[60]  Mary E. Choi,et al.  Transforming Growth Factor-β (TGF-β1) Activates TAK1 via TAB1-mediated Autophosphorylation, Independent of TGF-β Receptor Kinase Activity in Mesangial Cells* , 2009, The Journal of Biological Chemistry.

[61]  A. Bird.  DNA methylation patterns and epigenetic memory. , 2002, Genes & development.